Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

BACKGROUND: PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) with suboptimal LDL cholesterol (LDL...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Parth, Glueck, Charles J., Jetty, Vybhav, Goldenberg, Naila, Rothschild, Matan, Riaz, Rashid, Duhon, Gregory, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991071/
https://www.ncbi.nlm.nih.gov/pubmed/27538393
http://dx.doi.org/10.1186/s12944-016-0302-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991071/
https://www.ncbi.nlm.nih.gov/pubmed/27538393
http://dx.doi.org/10.1186/s12944-016-0302-8

Ejemplares similares